News & Articles

Study done at the University of Cambridge suggests a way to predict prognosis and most effective treatment in cancer

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer

Women with a rare type of ovarian cancer could benefit from a drug that quadruples the likelihood of response compared with standard therapies

Tell us which new products made the most difference to your lab work and you’ll have the chance to win one of four $500 Amazon gift cards

Study aims to develop a rapid point-of-care diagnostic based on multiple biomarkers to detect emergent sepsis

Abbott's new technology is poised to be the first point-of-care blood test for assessing concussions, providing doctors results in 15 minutes

Following last year’s success, we’re hosting our second annual event dedicated to celebrating our Seals of Quality program

Find out how one lab is streamlining the development of lentiviruses and transduction enhancers to treat a range of genetic diseases

Dr. John Connolly, CSO of Tessa Therapeutics, reveals how a new approach to cell-based therapy in cancer could circumvent severe immunotherapy side effects and effectively target aggressive solid tumors

New partnership to advance Nosopharm’s lead candidate to clinical stage

Phase 1 trial scheduled for early 2020 will be first CAR-T cell therapy clinical trial to employ SMARTvector technology

Attend this free expert webinar to learn about the applications of spectroscopy in clinical research

Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need

Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies

A small team of biotech scientists is targeting patient specific ‘neoantigens’ to improve response to adoptive T cell therapy in acute myeloid leukemia (AML)

Project to focus on data-driven cell conversions to produce cell therapies with potential application in wound healing, and oncology immunotherapy

The drug works by targeting the protein responsible for the death of heart cells during an attack

Immunology-focused pharma company INmune Bio is set to start first-in-man clinical trials with a promising anti-TNF compound that could revolutionize the treatment of Alzheimer’s disease and related symptoms

Scientists at the University of Southern California have identified blood-based biomarker patterns that indicate early-stage disease

Sativex® for the Treatment of AgitatioN in Dementia (STAND trial)